Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Show More...
-
Website https://www.synairgen.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.95 GBX
-
Last Updated 08-04-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2009-06 2010-06 2011-06 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 TTM Earnings Per Share GBP -0.1 -0.04 -0.05 -0.03 -0.03 0.010 -0.02 -0.03 0.02 -0.03 -0.03 Dividends GBP Payout Ratio % * Shares Mil 23.0 60.0 60.0 72.0 75.0 88.0 91.0 91.0 94.0 95.0 104.0 Book Value Per Share * GBP 0.05 0.03 0.05 0.09 0.07 0.04 0.05 0.02 Free Cash Flow Per Share * GBP -0.04 -0.03 0.03 -0.03 -0.02 -0.04 0.02 Return on Assets % -37.12 -34.56 -53.82 -57.01 -69.93 19.85 -24.76 -40.74 26.67 -45.64 -62.92 Financial Leverage (Average) 1.08 1.09 1.18 1.11 1.29 1.05 1.13 1.18 1.17 1.13 1.23 Return on Equity % -40.93 -37.6 -61.2 -68.82 -81.8 21.57 -26.87 -46.83 31.32 -52.46 -75.74 Return on Invested Capital % -42.75 -38.5 -61.79 -69.57 -82.2 21.14 -27.4 -47.35 31.12 -52.92 -76.34 Interest Coverage Current Ratio 12.72 10.93 6.09 8.82 3.77 19.82 8.74 6.36 6.89 8.24 5.0 Quick Ratio 12.48 10.26 5.8 7.9 2.83 19.39 8.24 5.59 6.72 7.04 3.73 Debt/Equity